September 17, 2015 10:30AM CSCO venue, Professor Liao Ning accepted CCMTV expert interview.Moderator: malignant bone metastases should be tr
September 17, 2015 10:30AM CSCO venue, Professor Liao Ning accepted CCMTV expert interview.
Moderator: malignant bone metastases should be treated as soon as possible, the use of bisphosphonates to prevent adverse events of bone metastases is what? Professor Liao Ning: 1, 2008 international guidelines for bisphosphonate: bone metastases after diagnosis began to receive bisphosphonate therapy, even if there is no diagnosis of symptoms. 2. ESMO guide, 2014: in order to delay the onset of adverse events of the first bone metastasis, and to reduce complications, it should be used once the diagnosis of bone metastasis occurs. 3, the domestic "malignant tumor bone metastasis and bone related diseases clinical diagnosis and treatment experts consensus 2014": clear breast cancer patients with bone metastasis, should first consider giving bisphosphonates as the basis of treatment.
Moderator: cause breast cancer treatment with aromatase inhibitors of bone loss, how do you treat patients? Professor Liao Ning: bisphosphonates are targeted at the bone to prevent bone loss, and bisphosphonates reduce bone metastasis and the risk of disease recurrence. Azole phosphonic acid caused by aromatase inhibitors in the prevention of bone loss of evidence comes from: Z-FAST, ZO-FAST, E-ZO-FAST, ABCSG-12, CALGB 79809 test of test, KCSG-BR06-01. Conclusion: for patients with early breast cancer before menopause, adjuvant chemotherapy in first years, every 6 months for 2 4Mg zoledronic acid injection can effectively prevent chemotherapy-induced bone loss; and should consider the regular measurement of bone mineral density and early initiation of bisphosphonate therapy.
Moderator: what is the long-term efficacy of bisphosphonates in the adjuvant treatment of early breast cancer? Professor Liao Ning: clinical trials have shown that the use of zoledronic acid in patients with breast cancer is based on ovarian suppression. A number of trials have shown that zoledronic acid has anti-tumor properties in patients with low estrogen levels: the ABCSG-12 study improves 28%DFS and ZO-FAST tests to improve 34%DFS and AZURE levels by up to 29%OS. July 24, 2015 in the lancet online document: postmenopausal breast cancer should be widely used bisphosphonate adjuvant therapy, there is a certain benefit.